151 related articles for article (PubMed ID: 22394167)
1. Targeting the cancer initiating cell: the ultimate target for cancer therapy.
McCubrey JA; Steelman LS; Abrams SL; Misaghian N; Chappell WH; Basecke J; Nicoletti F; Libra M; Ligresti G; Stivala F; Maksimovic-Ivanic D; Mijatovic S; Montalto G; Cervello M; Laidler P; Bonati A; Evangelisti C; Cocco L; Martelli AM
Curr Pharm Des; 2012; 18(13):1784-95. PubMed ID: 22394167
[TBL] [Abstract][Full Text] [Related]
2. Targeting the cancer initiating cell: the Achilles' heel of cancer.
McCubrey JA; Chappell WH; Abrams SL; Franklin RA; Long JM; Sattler JA; Kempf CR; Laidler P; Steelman LS
Adv Enzyme Regul; 2011; 51(1):152-62. PubMed ID: 21035484
[TBL] [Abstract][Full Text] [Related]
3. Lunasin is a novel therapeutic agent for targeting melanoma cancer stem cells.
Shidal C; Al-Rayyan N; Yaddanapudi K; Davis KR
Oncotarget; 2016 Dec; 7(51):84128-84141. PubMed ID: 27566591
[TBL] [Abstract][Full Text] [Related]
4. Possible role of mural cell-covered mature blood vessels in inducing drug resistance in cancer-initiating cells.
Matsui T; Kinugasa Y; Tahara H; Kanakura Y; Takakura N
Am J Pathol; 2013 May; 182(5):1790-9. PubMed ID: 23473746
[TBL] [Abstract][Full Text] [Related]
5. Reduction of MHC-I expression limits T-lymphocyte-mediated killing of Cancer-initiating cells.
Morrison BJ; Steel JC; Morris JC
BMC Cancer; 2018 Apr; 18(1):469. PubMed ID: 29699516
[TBL] [Abstract][Full Text] [Related]
6. MicroRNA-199a targets CD44 to suppress the tumorigenicity and multidrug resistance of ovarian cancer-initiating cells.
Cheng W; Liu T; Wan X; Gao Y; Wang H
FEBS J; 2012 Jun; 279(11):2047-59. PubMed ID: 22498306
[TBL] [Abstract][Full Text] [Related]
7. Immunomodulating and Immunoresistance Properties of Cancer-Initiating Cells: Implications for the Clinical Success of Immunotherapy.
Maccalli C; Parmiani G; Ferrone S
Immunol Invest; 2017 Apr; 46(3):221-238. PubMed ID: 28287848
[TBL] [Abstract][Full Text] [Related]
8. Critical role of Wnt/β-catenin signaling in driving epithelial ovarian cancer platinum resistance.
Nagaraj AB; Joseph P; Kovalenko O; Singh S; Armstrong A; Redline R; Resnick K; Zanotti K; Waggoner S; DiFeo A
Oncotarget; 2015 Sep; 6(27):23720-34. PubMed ID: 26125441
[TBL] [Abstract][Full Text] [Related]
9. Identification and functional analysis of variants of a cancer/testis antigen LEMD1 in colorectal cancer stem-like cells.
Takeda R; Hirohashi Y; Shen M; Wang L; Ogawa T; Murai A; Yamamoto E; Kubo T; Nakatsugawa M; Kanaseki T; Tsukahara T; Nishidate T; Okita K; Kutomi G; Sato N; Takemasa I; Torigoe T
Biochem Biophys Res Commun; 2017 Apr; 485(3):651-657. PubMed ID: 28219643
[TBL] [Abstract][Full Text] [Related]
10. Targeting cancer initiating cells by promoting cell differentiation and restoring chemosensitivity via dual inactivation of STAT3 and src activity using an active component of antrodia cinnamomea mycelia.
Chang CW; Chen YS; Chen CC; Chan IO; Chen CC; Sheu SJ; Lin TW; Chou SH; Liu CJ; Lee TC; Lo JF
Oncotarget; 2016 Nov; 7(45):73016-73031. PubMed ID: 27682875
[TBL] [Abstract][Full Text] [Related]
11. Targeting breast cancer initiating cells: advances in breast cancer research and therapy.
McCubrey JA; Davis NM; Abrams SL; Montalto G; Cervello M; Libra M; Nicoletti F; D'Assoro AB; Cocco L; Martelli AM; Steelman LS
Adv Biol Regul; 2014 Sep; 56():81-107. PubMed ID: 24913694
[TBL] [Abstract][Full Text] [Related]
12. Phosphorylation of HSF1 at serine 326 residue is related to the maintenance of gynecologic cancer stem cells through expression of HSP27.
Yasuda K; Hirohashi Y; Mariya T; Murai A; Tabuchi Y; Kuroda T; Kusumoto H; Takaya A; Yamamoto E; Kubo T; Nakatsugawa M; Kanaseki T; Tsukahara T; Tamura Y; Hirano H; Hasegawa T; Saito T; Sato N; Torigoe T
Oncotarget; 2017 May; 8(19):31540-31553. PubMed ID: 28415561
[TBL] [Abstract][Full Text] [Related]
13. Differential remodeling of extracellular matrices by breast cancer initiating cells.
Raja AM; Xu S; Zhuo S; Tai DC; Sun W; So PT; Welsch RE; Chen CS; Yu H
J Biophotonics; 2015 Oct; 8(10):804-15. PubMed ID: 25597396
[TBL] [Abstract][Full Text] [Related]
14. Brother of the regulator of the imprinted site (BORIS) variant subfamily 6 is involved in cervical cancer stemness and can be a target of immunotherapy.
Asano T; Hirohashi Y; Torigoe T; Mariya T; Horibe R; Kuroda T; Tabuchi Y; Saijo H; Yasuda K; Mizuuchi M; Takahashi A; Asanuma H; Hasegawa T; Saito T; Sato N
Oncotarget; 2016 Mar; 7(10):11223-37. PubMed ID: 26849232
[TBL] [Abstract][Full Text] [Related]
15. Annexin A3 as a potential target for immunotherapy of liver cancer stem-like cells.
Pan QZ; Pan K; Wang QJ; Weng DS; Zhao JJ; Zheng HX; Zhang XF; Jiang SS; Lv L; Tang Y; Li YQ; He J; Liu Q; Chen CL; Zhang HX; Xia JC
Stem Cells; 2015 Feb; 33(2):354-66. PubMed ID: 25267273
[TBL] [Abstract][Full Text] [Related]
16. Spelling Out CICs: A Multi-Organ Examination of the Contributions of Cancer Initiating Cells' Role in Tumor Progression.
Baisiwala S; Budhiraja S; Goel C; Nandoliya KR; Saathoff MR; Ahmed AU
Stem Cell Rev Rep; 2022 Jan; 18(1):228-240. PubMed ID: 34244971
[TBL] [Abstract][Full Text] [Related]
17. Cancer-initiating cells from colorectal cancer patients escape from T cell-mediated immunosurveillance in vitro through membrane-bound IL-4.
Volonté A; Di Tomaso T; Spinelli M; Todaro M; Sanvito F; Albarello L; Bissolati M; Ghirardelli L; Orsenigo E; Ferrone S; Doglioni C; Stassi G; Dellabona P; Staudacher C; Parmiani G; Maccalli C
J Immunol; 2014 Jan; 192(1):523-32. PubMed ID: 24277698
[TBL] [Abstract][Full Text] [Related]
18. MAPK13 is preferentially expressed in gynecological cancer stem cells and has a role in the tumor-initiation.
Yasuda K; Hirohashi Y; Kuroda T; Takaya A; Kubo T; Kanaseki T; Tsukahara T; Hasegawa T; Saito T; Sato N; Torigoe T
Biochem Biophys Res Commun; 2016 Apr; 472(4):643-7. PubMed ID: 26969274
[TBL] [Abstract][Full Text] [Related]
19. Promoted delivery of salinomycin sodium to lung cancer cells by dual targeting PLGA hybrid nanoparticles.
Zhou J; Sun J; Chen H; Peng Q
Int J Oncol; 2018 Sep; 53(3):1289-1300. PubMed ID: 30015824
[TBL] [Abstract][Full Text] [Related]
20. Olfactory Receptor Family 7 Subfamily C Member 1 Is a Novel Marker of Colon Cancer-Initiating Cells and Is a Potent Target of Immunotherapy.
Morita R; Hirohashi Y; Torigoe T; Ito-Inoda S; Takahashi A; Mariya T; Asanuma H; Tamura Y; Tsukahara T; Kanaseki T; Kubo T; Kutomi G; Mizuguchi T; Terui T; Ishitani K; Hashino S; Kondo T; Minagawa N; Takahashi N; Taketomi A; Todo S; Asaka M; Sato N
Clin Cancer Res; 2016 Jul; 22(13):3298-309. PubMed ID: 26861454
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
